BFM
CRBP icon

Boothbay Fund Management’s Corbus Pharmaceuticals CRBP Stock Holding History

Boothbay Fund Management’s Portfolio CRBP Stock Details CRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-10,534
Closed -$124K – 1463
2024
Q4 		$124K Sell
10,534
-72,084
-87% -$1.21M ﹤0.01% 1257
2024
Q3 		$1.7M Sell
82,618
-3,731
-4% -$191K 0.04% 576
2024
Q2 		$3.91M Sell
86,349
-69,664
-45% -$2.93M 0.09% 297
2024
Q1 		$6.12M Buy
156,013
+114,398
+275% +$2.82M 0.12% 171
2023
Q4 		$251K Hold
41,615
– – 0.01% 1256
2023
Q3 		$280K Buy
41,615
+3,639
+10% +$25.2K 0.01% 1276
2023
Q2 		$298K Hold
37,976
– – 0.01% 1304
2023
Q1 		$276K Buy
37,976
+36,645
+2,753% +$160K 0.01% 1561
2022
Q4 		$4.41K Hold
1,331
– – ﹤0.01% 1943
2022
Q3 		$7K Sell
1,331
-1,831
-58% -$12.9K ﹤0.01% 2183
2022
Q2 		$24K Sell
3,162
-18
-0.6% -$174 ﹤0.01% 2178
2022
Q1 		$51K Hold
3,180
– – ﹤0.01% 2179
2021
Q4 		$59K Hold
3,180
– – ﹤0.01% 1767
2021
Q3 		$97K Sell
3,180
-1,098
-26% -$43.3K ﹤0.01% 1802
2021
Q2 		$235K Buy
4,278
+579
+16% +$32.1K 0.01% 1421
2021
Q1 		$219K Buy
3,699
+3,209
+655% +$211K 0.01% 1325
2020
Q4 		$18K Buy
+490
New +$18.3K ﹤0.01% 1202

Other funds holding CRBP

CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Boothbay Fund Management's CRBP Position: Q1 2025 in Review

Boothbay Fund Management sold out of Corbus Pharmaceuticals (CRBP) in Q1 2025, closing a stake of 10,534 shares — an estimated $124K sold.

Boothbay Fund Management first reported a position in CRBP in Q4 2020 and held it in 17 quarters. The position peaked at $6.12M in Q1 2024. 86 funds tracked by Wall St. Rank hold CRBP as of Q1 2025.

  • Boothbay Fund Management reported no remaining Corbus Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Boothbay Fund Management sold 10,534 Corbus Pharmaceuticals shares in Q1 2025, an estimated $124K.
  • Boothbay Fund Management first reported a position in Corbus Pharmaceuticals in Q4 2020 and held it in 17 quarters.
  • Boothbay Fund Management's Corbus Pharmaceuticals position peaked at $6.12M in Q1 2024.
  • 86 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q1 2025.

Based on Boothbay Fund Management's 13F filing for Q1 2025, filed 15 May 2025.